Home/ Stocks/ OTLK

Outlook Therapeutics, Inc. Common Stock

OTLK XNAS

$1.02 +0.05 (+4.88%) ▲ 15-min delayed

Open

$0.99

High

$1.04

Low

$0.95

Volume

4.55M

Market Cap

$181.85M

About Outlook Therapeutics, Inc. Common Stock

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$3	$-4,453,081	$-0.05
Q1 2026	$-1,237,459	$-23,058,135	$-0.38
FY 2025	$1.41M	$-62,424,863	$-1.79
Q3 2025	$1.51M	$-20,152,502	$-0.55

Related Market News

No specific coverage for OTLK yet. Check out our latest market news or earnings calendar.

Get OTLK Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Outlook Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.